Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-?-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bioavailability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.

Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-?-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bioavailability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.

Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bio availability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.

Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bio availability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.

Abstract: The present invention concerns an aqueous pharmaceutical composition for bladder instillation, cystitis therapy, or interstitial cystitis therapy, the aqueous composition containing water, hyaluronic acid or a salt thereof and/or chondroitin sulphate or a salt thereof, and a pharmaceutically acceptable bivalent metal ion, wherein the bivalent metal ion is chosen from calcium and magnesium, and wherein the bivalent ion lowers the viscosity of the composition.

Abstract: The present invention relates to injectable progesterone formulations and processes for their preparation.

Abstract: The present invention concerns new compositions comprising glycosaminoglycans, intended for use in interstitial cystitis therapy, and characterized by a controlled viscosity.

Abstract: Injectable pharmaceutical compositions are described comprising sodium diclofenac, a ?-cyclodextrin and a polysorbate, suitable for subcutaneous and intramuscular administration.

Abstract: The present invention relates to injectable progesterone formulations and processes for their preparation.

Abstract: Injectable pharmaceutical compositions are described comprising sodium diclofenac, a ?-cyclodextrin and a polysorbate, suitable for subcutaneous and intramuscular administration.